Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Acquired by Mackenzie Financial Corp

Mackenzie Financial Corp lifted its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 255.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 76,353 shares of the company’s stock after buying an additional 54,850 shares during the quarter. Mackenzie Financial Corp owned 0.06% of Organogenesis worth $244,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Soleus Capital Management L.P. raised its stake in shares of Organogenesis by 5.4% during the fourth quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company’s stock valued at $39,952,000 after purchasing an additional 645,000 shares during the period. Virtus Investment Advisers Inc. acquired a new stake in Organogenesis during the 4th quarter valued at $157,000. Squarepoint Ops LLC increased its stake in Organogenesis by 53.2% during the 4th quarter. Squarepoint Ops LLC now owns 126,791 shares of the company’s stock worth $406,000 after buying an additional 44,051 shares during the period. Two Sigma Investments LP lifted its holdings in Organogenesis by 25.9% in the 4th quarter. Two Sigma Investments LP now owns 382,406 shares of the company’s stock worth $1,224,000 after buying an additional 78,744 shares in the last quarter. Finally, ProShare Advisors LLC boosted its position in Organogenesis by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company’s stock valued at $65,000 after buying an additional 6,689 shares during the last quarter. 49.57% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley raised their target price on Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th.

Organogenesis Stock Performance

Shares of ORGO opened at $2.88 on Friday. The firm has a market cap of $365.34 million, a price-to-earnings ratio of -48.00 and a beta of 1.85. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. The business’s 50 day moving average is $3.85 and its two-hundred day moving average is $3.86. Organogenesis Holdings Inc. has a 52-week low of $2.28 and a 52-week high of $6.71.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.17). The company had revenue of $86.69 million during the quarter, compared to analyst estimates of $90.77 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. Analysts forecast that Organogenesis Holdings Inc. will post -0.07 EPS for the current fiscal year.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.